Increasing use of immune checkpoint inhibitors (ICIs) for the treatment of cancer has led to an increasing incidence of immune related adverse events (irAEs). Cutaneous toxicities are some of the most common irAE manifestations, but clinicians may be less trained to recognize signs and symptoms in non-White patients. Social determinants of health that may impact a patient’s ability to receive recommended treatment for irAEs include geographic location, transportation difficulties, low income, and language barriers. Implicit and explicit biases may impact a patient’s ability to receive guideline-recommended care from healthcare team members. Focused efforts are needed to address health care inequities in patients being treated with ICIs and to improve chances of achieving the best possible outcomes for all patients. Clinicians need to incorporate considerations for health care disparities into care planning to effectively manage irAEs in historically disadvantaged patient populations.
In this CMEO BriefCase, expert faculty will present information on how healthcare disparities impact irAE recognition and management and pharmacist considerations for social determinants of health relative to irAE diagnosis and treatment planning. Discussion will include strategies for addressing healthcare inequities in order to improve timely recognition and treatment for all patients experiencing irAEs.
Upon completion of this activity, learners will be better able to develop tactics for addressing health care disparities in patients experiencing irAEs.
Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Pharmacists in outpatient, ambulatory, or community care settings.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Ajewole reports no financial relationships to disclose.
Dr. Velázquez Mañana reports the following financial relationships:
Advisory Board: AstraZeneca
Stock Shareholder (directly purchased): Corbus Pharmaceuticals Holdings, Inc.
Other Financial or Material Support: Honoraria: Curio Science and MJH Life Sciences; Travel/accommodations: Bio Ascend and DAVA
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).